Kasemchaiyanun Akarawut, Boonsarngsuk Viboon, Liamsombut Somprasong, Incharoen Pimpin, Sukkasem Warawut
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Respir Med Case Rep. 2022 Jun 30;38:101690. doi: 10.1016/j.rmcr.2022.101690. eCollection 2022.
Denosumab is a bone anti-resorptive drug, commonly used for treating osteoporosis. Pulmonary involvement has rarely been reported as a possible serious adverse effect of this medication. Herein, we report the case of a 67-year-old woman who presented with non-massive hemoptysis, anemia, and extensive pulmonary opacities on a chest radiograph for 3 days after receiving denosumab. The patient was diagnosed with myeloperoxidase-antineutrophil cytoplasmic antibody-associated pulmonary hemorrhage secondary from denosumab. She was treated with high doses of intravenous methylprednisolone and cyclophosphamide combined with plasmapheresis. Subsequently, her clinical and radiological findings improved without residual abnormalities after treatment.
地诺单抗是一种骨抗吸收药物，常用于治疗骨质疏松症。肺部受累作为该药物可能的严重不良反应鲜有报道。在此，我们报告一例67岁女性患者，在接受地诺单抗治疗3天后出现非大量咯血、贫血，胸部X线片显示广泛肺部阴影。该患者被诊断为地诺单抗继发的髓过氧化物酶-抗中性粒细胞胞浆抗体相关性肺出血。她接受了大剂量静脉注射甲泼尼龙和环磷酰胺联合血浆置换治疗。随后，治疗后其临床和影像学表现改善，未遗留异常。
